Anavex Life Sciences AVXL Stock
Anavex Life Sciences Price Chart
Anavex Life Sciences AVXL Financial and Trading Overview
| Anavex Life Sciences stock price | 3.72 USD |
| Previous Close | 8.75 USD |
| Open | 8.76 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 8.59 - 8.94 USD |
| 52 Week Range | 7.44 - 15.24 USD |
| Volume | 827.57K USD |
| Avg. Volume | 997.59K USD |
| Market Cap | 713.8M USD |
| Beta (5Y Monthly) | 0.73345 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.54 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.75 USD |
AVXL Valuation Measures
| Enterprise Value | 553.86M USD |
| Trailing P/E | N/A |
| Forward P/E | -14.015873 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.88115 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Anavex Life Sciences Stock Price History
| Beta (5Y Monthly) | 0.73345 |
| 52-Week Change | 4.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.24 USD |
| 52 Week Low | 7.44 USD |
| 50-Day Moving Average | 8.65 USD |
| 200-Day Moving Average | 9.8 USD |
AVXL Share Statistics
| Avg. Volume (3 month) | 997.59K USD |
| Avg. Daily Volume (10-Days) | 1.22M USD |
| Shares Outstanding | 80.84M |
| Float | 78.3M |
| Short Ratio | 19.34 |
| % Held by Insiders | 2.95% |
| % Held by Institutions | 34.53% |
| Shares Short | 16.51M |
| Short % of Float | 21.03% |
| Short % of Shares Outstanding | 20.41% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.19% |
| Return on Equity (ttm) | -35.46% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -52736736 USD |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 153.47M USD |
| Total Cash Per Share (mrq) | 1.9 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 11.353 |
| Book Value Per Share (mrq) | 1.809 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25380260 USD |
| Levered Free Cash Flow (ttm) | -7335369 USD |
Profile of Anavex Life Sciences
| Country | United States |
| State | NY |
| City | New York |
| Address | 630 5th Avenue |
| ZIP | 10111 |
| Phone | 844 689 3939 |
| Website | https://www.anavex.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 38 |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Q&A For Anavex Life Sciences Stock
What is a current AVXL stock price?
Anavex Life Sciences AVXL stock price today per share is 3.72 USD.
How to purchase Anavex Life Sciences stock?
You can buy AVXL shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Anavex Life Sciences?
The stock symbol or ticker of Anavex Life Sciences is AVXL.
Which industry does the Anavex Life Sciences company belong to?
The Anavex Life Sciences industry is Biotechnology.
How many shares does Anavex Life Sciences have in circulation?
The max supply of Anavex Life Sciences shares is 89.35M.
What is Anavex Life Sciences Price to Earnings Ratio (PE Ratio)?
Anavex Life Sciences PE Ratio is now.
What was Anavex Life Sciences earnings per share over the trailing 12 months (TTM)?
Anavex Life Sciences EPS is -0.54 USD over the trailing 12 months.
Which sector does the Anavex Life Sciences company belong to?
The Anavex Life Sciences sector is Healthcare.
Anavex Life Sciences AVXL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23613.31 USD — |
+0.22
|
3.54B USD — | 23527.97 USD — | 23621.72 USD — | — - | 3.54B USD — |
| US Tech Global Select Market Com NQGS | 11566.45 USD — |
+0.21
|
— — | 11525.25 USD — | 11570.56 USD — | — - | — — |
| US Tech Biotechnology NBI | 5843.74 USD — |
+0.69
|
— — | 5812.05 USD — | 5851.25 USD — | — - | — — |
| US Tech Health Care IXHC | 1212.11 USD — |
+0.55
|
— — | 1206.25 USD — | 1213.6 USD — | — - | — — |
| US Tech Capital Market Composite RCMP | 133.06 USD — |
+0.23
|
— — | 131.86 USD — | 133.42 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}